Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $281.67M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 2.02M
Average 2.06M
Income Statement
Follow revenue through to earnings.
Revenue
$40.52M
FY 2025 · Annual
+25.4% YoYOperating Income
-$99.34M
FY 2025 · Annual
Net Income
-$160.06M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Cost of Revenue | 5.05M | 6.34M | 6.06M | 199.25M | 0 |
| Gross Profit | 20.49M | 13.38M | 72.06M | (166.93M) | 40.52M |
| Gross Margin | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| Research & Development | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
| Selling, General & Admin | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M |
| Operating Expenses | 213.64M | 239.33M | 241.24M | 84.22M | 139.86M |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| EBITDA | (187.45M) | (214.1M) | (147.16M) | (233.11M) | (148.61M) |
| EBITDA Margin | -733.8% | -1086.1% | -188.4% | -721.4% | -366.8% |
| Operating Income | (193.15M) | (225.95M) | (169.18M) | (251.15M) | (99.34M) |
| Operating Margin | -756.1% | -1146.3% | -216.6% | -777.2% | -245.2% |
| Interest Income | 607K | 5.52M | 17.57M | 14.06M | 8.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 6.17M |
| Other Income / Expenses | 644K | 5.52M | 15.96M | 14.06M | (60.72M) |
| Income Before Tax | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Pre-Tax Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Net Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (Basic) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| EPS (Diluted) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| 67.62M | 68.66M | 75.97M | 82.34M | 88.75M | |
| 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
EDIT Earnings Waterfall · TTM
NASDAQ:EDIT · Revenue to Net Income
Key Ratios
Analysis
$38.7M of revenue converted into -$109.0M of net income for the selected period. Gross margin is -82.9% and net margin is -681.5%, showing how much revenue survives after costs and taxes. EPS is $-1.23, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
How much revenue does EDIT generate?
Editas Medicine, Inc. (EDIT) reported $40.52M of revenue in fiscal 2025.
Is EDIT profitable?
Editas Medicine, Inc. (EDIT) reported -$160.06M of net income, with a net margin of -395.0%.
Continue the stock analysis
Jump to another research area for this company.